Group letter re: DEA’s proposed rule on controlled substances quotas

May 4, 2018

RE: Controlled Substances Quotas [Docket No. DEA-480]

The undersigned groups thank the Drug Enforcement Administration (DEA) for the opportunity to comment on its proposed rule regarding controlled substances quotas. Although we support DEA’s efforts to combat diversion, we are concerned that the proposed rule is focused on diversion to the exclusion of another critical factor – drug shortages. To ensure that legitimate medical needs are met, it is imperative that drug shortages be considered as aggregate production quotas (APQ) are set and adjusted.


Read the full letter below.

Related Resources

Letter
Public
AHA expresses disappointment that the Agency for Healthcare Research and Quality is shutting down the National Guidelines Clearinghouse.
Letter
Public
AHA comments on the Department of Health and Human Services’ Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Action Alert
Member
On June 25, the Centers for Medicare & Medicaid Services (CMS) published
Letter
Member
The AHA is very pleased that CMS is taking action to improve the operation of the Stark law and counteract its chilling effect on innovation.
Special Bulletin
Member
The Centers for Medicare…
Resources
Member
Advocacy update, news, and more. Download the cover note below.